$CHRS News

Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology, Inc. Q2 2026 Earnings Call Summary

Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Coherus BioSciences Q2 Adj. EPS $(0.19) Beats $(0.20) Estimate, Sales $14.307M Miss $14.400M Estimate

Coherus Oncology: The Catalyst Rich Period Is Here

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus Announces Clinical Collaboration And Supply Agreement With Zumutor To Conduct Phase 1 Trial Of ZM008, NK Checkpoint Anti-LLT1 Monoclonal Antibody In Combination With LOQTORZI

What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today

Coherus Oncology: Setting Up For Important Readouts In Mid-2026

Coherus Oncology, Inc. Q1 2026 Earnings Call Summary

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript